Comparison of chemotherapeutic treatment outcomes of advanced extrapulmonary neuroendocrine carcinomas and advanced small-cell lung carcinoma

Neuroendocrinology

Volumn 96, Issue 4, 2012, Pages 324-332

  Terashima, T ^a,e   Morizane, C ^a   Hiraoka, N ^d   Tsuda, H ^b   Tamura, T ^c   Shimada, Y ^a   Kaneko, S ^e   Kushima, R ^b   Ueno, H ^a   Kondo, S ^a   Ikeda, M ^f   Okusaka, T ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b Pathology Division   (Japan)

^c Internal Medicine and Thoracic Oncology Division   (Japan)

^d NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^e KANAZAWA UNIVERSITY HOSPITAL   (Japan)

^f NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

Chemotherapy; Extrapulmonary neuroendocrine carcinoma; Prognosis; Prognostic factor; Small cell lung carcinoma

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE; IRINOTECAN;

ADULT; ADVANCED CANCER; AGED; BILE DUCT CARCINOMA; BLADDER CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER OF UNKNOWN PRIMARY SITE; CANCER PROGNOSIS; CANCER SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; ESOPHAGUS CARCINOMA; FEMALE; GALLBLADDER CARCINOMA; HUMAN; LIVER CELL CARCINOMA; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NEUROENDOCRINE TUMOR; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROSTATE CARCINOMA; REVIEW; STOMACH CARCINOMA; THYMUS CANCER; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NEUROENDOCRINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; RETROSPECTIVE STUDIES; SMALL CELL LUNG CARCINOMA; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84871606939     PISSN: 00283835     EISSN: 14230194     Source Type: Journal    
DOI: 10.1159/000338794     Document Type: Review

References (40)

1. Barakat MT, Meeran K, Bloom SR: Neuroendocrine tumours. Endocr Relat Cancer 2004; 11:1-18.
2. Rindi G, Arnold R, Bosman FT, et al: Nomenclature and classification of neuroendocrine neoplasms of the digestive system. WHO classification of tumours of the digestive system. Lyon, IARC Press, 2010.
3. Dugu id J, Kennedy A: Oat-cel l t umors of me-diastinal glands. J Pathol Bacteriol 1930; 33: 93-99.
4. Brennan SM, Gregory DL, Stillie A, Hersch-tal A, Mac Manus M, Ball DL: Should extra-pulmonary small cell cancer be managed like small cell lung cancer? Cancer 2010; 116: 888-895.
5. Brenner B, Shah MA, Gonen M, Klimstra DS, Shia J, Kelsen DP: Small-cell carcinoma of the gastrointestinal tract: a retrospective study of 64 cases. Br J Cancer 2004; 90:1720-1726.
6. Brenner B, Tang LH, Klimstra DS, Kelsen DP: Small-cell carcinomas of the gastrointestinal tract: a review. J Clin Oncol 2004; 22: 2730-2739.
7. Cicin I, Karagol H, Uzunoglu S, Uygun K, Usta U, Kocak Z, et al: Extrapulmonary small-cell carcinoma compared with small-cell lung carcinoma: a retrospective singlecenter study. Cancer 2007; 110: 1068-1076.
8. Galanis E, Frytak S, Lloyd RV: Extrapulmo-nary sma ll cell carcinoma. Cancer 1997; 79: 1729-1736.
9. Haider K, Shahid RK, Finch D, Sami A, Ahmad I, Yadav S, et al: Extrapulmonary small cell cancer: a Canadian province's experience. Cancer 2006; 107:2262-2269.
10. Kim JH, Lee SH, Park J, Kim HY, Lee SI, Nam EM, et al: Extrapulmonary small-cell carcinoma: a single-institution experience. Jpn J Clin Oncol 2004; 34: 250-254.
11. Lee SS, Lee JL, Ryu MH, Chang HM, Kim TW, Kim WK, et al: Extrapulmonary small cell carcinoma: single center experience with 61 patients. Acta Oncol 2007; 46:846-851.
12. Lin YL, Chung CY, Chang CS, Wu JS, Kuo KT, Kuo SH, et al: Prognostic factors in ex-trapulmonary small cell carcinomas. A large retrospective study. Oncolog y 2007; 72: 181-187.
13. Moskal TL, Zhang PJ, Nava HR: Small cell carcinoma of the gallbladder. J Surg Oncol 1999; 70:54-59.
14. Takubo K, Nakamura K, Sawabe M, Arai T, Esaki Y, Miyashita M, et al: Primary undif-ferentiated small cell carcinoma of the esophagus. Hum Pathol 1999; 30:216-221.
15. Walenkamp AM, Sonke GS, Sleijfer DT: Clinical and therapeutic aspects of extrapul-monary small cell carcinoma. Cancer Treat Rev 2009; 35: 228-236.
16. Wong YN, Jack RH, Mak V, Henrik M, Da-vies EA: The epidemiology and survival of extrapulmonary small cell carcinoma in South East England, 1970-2004. BMC Cancer 2009; 9: 209.
17. Ahlman H, Nilsson O, McNicol AM, Ruszniewski P, Niederle B, Ricke J, et al: Poorly-differentiated endocrine carcinomas of midgut and hindgut origin. Neuroendo-crinology 2008; 87:40-46.
18. Nilsson O, Van Cutsem E, Delle Fave G, Yao JC, Pavel ME, McNicol AM, et al: Poorly differentiated carcinomas of the foregut (gastric, duodenal and pancreatic). Neuroendo-crinology 2006; 84:212-215.
19. Fjallskog ML, Granberg DP, Welin SL, Eriksson C, Oberg KE, Janson ET, et al: Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer 2001; 92: 1101-1107.
20. Mitry E, Baudin E, Ducreux M, Sabourin JC, Rufie P, Aparicio T, et al: Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer 1999; 81: 1351-1355.
21. Moertel CG, Kvols LK, O'Connell MJ, Rubin J: Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991; 68:227-232.
22. Janson ET, Holmberg L, Stridsberg M, Eriksson B, Theodorsson E, Wilander E, et al: Car-cinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol 1997; 8:685-690.
23. Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC; WHO, IARC (eds): World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon, IARC Press, 2004.
24. DeLellis RA; WHO, IARC (eds): World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Endocrine Organs. Lyon, IARC Press, 2004.
25. Zelen M: Keynote address on biostatistics and data retrieval. Cancer Chemother Rep 31973; 4:31-42.
26. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216.
27. Kaplan E, Meier P: Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958; 53: 457-481.
28. Cox D: Regression models and life-tables. J R Stat Soc B 1972; 34: 187-200.
29. Rindi G, Kloppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, et al: TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006; 449: 395-401.
30. Rindi G, Kloppel G, Couvelard A, Kommi-noth P, Korner M, Lopes JM, et al: TNM staging of midgut and hindgut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2007; 451: 757-762.
31. Kloppel G. Tumour biology and histopathol-ogy of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 2007; 21: 15-31.
32. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al: One hundred years after 'carcinoid': epidemiology of and prognostic factors for neuroendocrine tumors in 35, 825 cases in the United States. J Clin Oncol 2008; 26: 3063-3072.
33. Fukuoka M, Furuse K, Saijo N, Nishiwaki Y, Ikegami H, Tamura T, et al: Randomized t rial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 1991; 83: 855-861.
34. Hanna N, Bunn PA Jr, Langer C, Einhorn L, Guthrie T Jr, Beck T, et al: Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 2006; 24: 2038-2043.
35. Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, et al: Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002; 346: 85-91.
36. Okamoto H, Watanabe K, Kunikane H, Yo-koyama A, Kudoh S, Asakawa T, et al: Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus eto-poside in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702. Br J Cancer 2007; 97:162-169.
37. Bettini R, Boninsegna L, Mantovani W, Ca-pelli P, Bassi C, Pederzoli P, et al: Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours. Ann Oncol 2008; 19: 903-908.
38. Kouvaraki MA, Ajani JA, Hoff P, Wolff R, Evans DB, Lozano R, et al: Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 2004; 22:4762-4771.
39. Madeira I, Terris B, Voss M, Denys A, Sau-vanet A, Flejou JF, et al: Prognostic factors in patients with endocrine tumours of the duo-denopancreatic area. Gut 1998; 43:422-427.
40. Panzuto F, Nasoni S, Falconi M, Corleto VD, Capurso G, Cassetta S, et al: Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer 2005; 12:1083-1092.